Polypharmacy and multimorbidity in Post-polio syndrome: Evidence of risks?

• Autor(a) principal: Conti, Mônica de Souza Brito
• Data de Publicação: 2022
• Outros Autores: Quadros , Abrahão Augusto Joviniano, Campos, Marília Silveira de Almeida, Oliveira, Acary Souza Bulle, Pereira , Leonardo Régis Leira
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/24951
• topic: Síndrome Pós-Poliomielite; Doenças crônicas; Multimorbidade; Polimedicação.; Síndrome Pospoliomielitis; Enfermedad Crónica; Multimorbilidad; Polifarmacia.; Postpoliomyelitis Syndrome; Chronic diseases; Multimorbidity; Polypharmacy.

The Post-poliomyelitis Syndrome (PPS) has as a therapeutic measure the use of medications for its symptoms; however, the use of different drugs for other morbidities is also perceived. The article aimed to investigate the pharmacotherapeutic profile of patients with PPS treated at a Brazilian tertiary outpatient clinic, as well as the practice of polypharmacy and its association with demographic and socioeconomic indicators, chronic diseases and symptoms of PPS. A descriptive, cross-sectional study was carried out with 150 patients diagnosed with PPS, and through a form, demographic, socioeconomic, clinical and pharmacotherapeutic data were obtained. The mean age of patients was 53 years; 74% female; 42.6% with 13 years of study or more; 93.3% with their own economic income and 96% of independent patients with other morbidities with an average of 4 morbidities/patient, with Arterial Hypertension being the most prevalent (45%). Patients used up to 14 medications, with an average of 5 medications/patient – presence of Polypharmacy (52%); 72.6% used medications that act on the nervous system – higher prevalence of antidepressants. It was found by the Chi-square test, statistically significant associations p<0.05 with the independent variables “female gender”, “morbidities”, “never smoked”, “not use medications as prescribed by the doctor”, “have clinical characteristics of the SPP: cold intolerance”. Given the evidence of risks, it is necessary to provide a necessary, safe, effective and rational pharmacotherapy for a better quality of life in this population, since the pharmacotherapeutic reality presented can cause risks, decreasing or worsening their functional status.